OBJECTIVE: To characterize the relative levels of the ErbB family of receptors and their relationship to one another in @entity43 . METHODS: A total of 17 @entity19862 were analyzed for @entity470 ( @entity470 or @entity470 ) and @entity1722 , @entity7514 , and @entity12251 receptor expression by Western blot analysis. Receptor levels were quantified by densitometry and expressed as relative densitometry units normalized to the level of alpha-tubulin. Linear regression analysis was used to analyze receptor group differences. A value of P < or = .05 was considered statistically significant. RESULTS: All 17 @entity5 expressed detectable levels of @entity470 , @entity1722 , and @entity7514 , but @entity12251 expression was not detected. @entity470 levels correlated with @entity1722 (r = .70, P < .01) and @entity7514 (r = .52, P < .05) levels. The highest correlation was obtained between the levels of @entity1722 and @entity7514 (r = 0.81, P < .001). CONCLUSION: This study indicates an association between the levels of ErbB receptor family members in @entity43 . This association suggests that one or more coordinated regulatory mechanisms may be involved in determining their relative expression levels to one another.

Expression of the ErbB family of receptors in XXXX .

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity7514 :: ('2065', 'Gene') :: ['ErbB-3'] @entity470 :: ('1956', 'Gene') :: ['ErbB-1', 'epidermal growth factor receptor', 'EGF-R'] @entity12251 :: ('2066', 'Gene') :: ['ErbB-4'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity19862 :: ('MESH:D018284', 'Disease') :: ['serous cystadenocarcinomas'] @entity1722 :: ('2064', 'Gene') :: ['ErbB-2']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']
